autologous anti-CLDN18.2 TAC T cells TAC01-CLDN18.2

{
  "id": "MLC-T-ONC-011415",
  "term": "autologous anti-CLDN18.2 TAC T cells TAC01-CLDN18.2",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of autologous T lymphocytes that have been genetically engineered to express a T-cell Antigen Coupler (TAC), comprised of a domain that targets the tumor-associated antigen (TAA) claudin 18.2 (CLDN18.2; A2 isoform of claudin-18) and another domain that binds to the endogenous T-cell receptor (TCR), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CLDN18.2 TAC T cells TAC01-CLDN18.2 target and bind to CLDN18.2-expressing tumor cells and activate TCR-mediated signaling pathways, leading to T-cell-mediated killing of CLDN18.2-expressing tumor cells. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells. Its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.",
  "synonyms": [
    "autologous anti-claudin 18.2 TAC-T cells TAC01-CLDN18.2",
    "autologous anti-CLDN18.2 T-cell antigen coupler-expressing T cells TAC01-CLDN18.2",
    "TAC-engineered T cells TAC01-CLDN18.2"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/autologous-anti-cldn18-2-tac-t-cells-tac01-cldn18-2/"
}